Concizumab
CAS No. 1312299-39-0
Concizumab ( —— )
产品货号. M36873 CAS No. 1312299-39-0
Concizumab 是一种 抗 TFPI 单克隆抗体 (IgG4 型),可与 TFPI 的 Kunitz 型蛋白酶抑制剂 (KPI) 2 结构域结合,从而阻断该结构域与 FXa 活性位点的相互作用。Concizumab 可用于血友病的研究。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥5216 | 有现货 |
|
| 10MG | ¥7106 | 有现货 |
|
| 25MG | ¥10137 | 有现货 |
|
| 50MG | ¥13764 | 有现货 |
|
| 100MG | ¥17820 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Concizumab
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Concizumab 是一种 抗 TFPI 单克隆抗体 (IgG4 型),可与 TFPI 的 Kunitz 型蛋白酶抑制剂 (KPI) 2 结构域结合,从而阻断该结构域与 FXa 活性位点的相互作用。Concizumab 可用于血友病的研究。
-
产品描述Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. Concizumab can be used in the study of haemophilia.
-
体外实验——
-
体内实验Animal Model:Cynomolgus monkeys (target mediated drug disposition (TMDD) model).Dosage:20mg/kg or 200 mg/kg Administration:Intravenous injection/subcutaneous injection Result:Showed a high bioavailability (93%) and the absorption half-life is estimated to be 72 h.
-
同义词——
-
通路Others
-
靶点Other Targets
-
受体Others
-
研究领域——
-
适应症——
化学信息
-
CAS Number1312299-39-0
-
分子量
-
分子式——
-
纯度>98% (HPLC)
-
溶解度——
-
SMILES——
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Kjalke M, et al. Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses. J Thromb Haemost. 2021 Jul;19(7):1687-1696. ?
产品手册
关联产品
-
OD1
Potent rat Nav1.7, human Nav1.4 and rat Nav1.6 channel activator (EC50 values are 7, 10 and 47 nM, respectively). Exhibits minimal activation at mammalian Nav1.2, Nav1.3 and Nav1.5 (EC50 values >3 μM). Inhibits fast inactivation on all channels. Increases peak currents at all voltages and stimulates a persistent Na+ current at hNav1.7 channel. Increases hyperpolarization at Nav1.4 and Nav1.6 channels. Induces spontaneous pain in vivo.
-
N-terminally acetyla...
N-terminally acetylated Endomorphin-1 is a modified Endomorphin-1.
-
BRD7716
BRD7116 竞争性地结合细菌 DNA 旋转酶,具有细胞非自主抗白血病活性。
021-51111890
购物车()
sales@molnova.cn

